These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11988061)

  • 1. Needlestick transmission of hepatitis C.
    Sulkowski MS; Ray SC; Thomas DL
    JAMA; 2002 May; 287(18):2406-13. PubMed ID: 11988061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers.
    Corey KE; Servoss JC; Casson DR; Kim AY; Robbins GK; Franzini J; Twitchell K; Loomis SC; Abraczinskas DR; Terella AM; Dienstag JL; Chung RT
    Infect Control Hosp Epidemiol; 2009 Oct; 30(10):1000-5. PubMed ID: 19743901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of seroconversion in a health care worker after polymerase chain reaction-documented acute hepatitis C resulting from a needlestick injury.
    Morand P; Dutertre N; Minazzi H; Burnichon J; Pernollet M; Baud M; Zarski JP; Seigneurin JM
    Clin Infect Dis; 2001 Sep; 33(5):727-9. PubMed ID: 11477531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
    AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
    Osinusi A; Rasimas JJ; Bishop R; Proschan M; McLaughlin M; Murphy A; Cortez KJ; Polis MA; Masur H; Rosenstein D; Kottilil S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):357-63. PubMed ID: 20101190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.
    Scaggiante R; Chemello L; Rinaldi R; Bartolucci GB; Trevisan A
    World J Gastroenterol; 2013 Jan; 19(4):581-5. PubMed ID: 23382640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection.
    McGovern BH; Nagami EH; Birch CE; Bowen MJ; Reyor LL; Chung RT; Kim AY
    J Infect Dis; 2009 Sep; 200(6):877-81. PubMed ID: 19673649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early therapy with interferon for acute hepatitis C acquired through a needlestick.
    Noguchi S; Sata M; Suzuki H; Ohba K; Mizokami M; Tanikawa K
    Clin Infect Dis; 1997 May; 24(5):992-4. PubMed ID: 9142809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C.
    Golstein PE; Delforge ML; Deviere J; Marcellin P
    J Viral Hepat; 2004 Mar; 11(2):183-6. PubMed ID: 14996354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.
    U.S. Public Health Service
    MMWR Recomm Rep; 2001 Jun; 50(RR-11):1-52. PubMed ID: 11442229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.